TLSA - Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress Following-Up From Positive Outcomes Data Presented In June | Benzinga
Tiziana (NASDAQ: TLSA) is following up with anticipated human data and announced the acceptance of a late-breaking poster at the 39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) being held in Milan, Italy, October 11-13, 2023. The company will present a poster titled, "Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes”, which is a follow-up from the positive data presented in June on 5 out of 6 patients.
The key takeaway is that Tiziana’s research through its FDA authorized Expanded Access program has shown continued improvement in SPMS patients over time treated with foralumab, the Company’s intranasally administered anti-CD3 monoclonal antibody. In June, Tiziana announced a reduction in microglial activation as seen in 3-month Positron Emission Tomography (PET) scans in a total of 5 of 6 patients treated. The ...